

FIG. 1A




FIG. 1B




FIG. 1C





FIG. 1D






FIG. 2




FIG. 3





FIG. 4






FIG. 5A



பு.கே.பி.

+	Stimulates
=	Regulates
C	Consumes
D	Decreases
F	Flows
I	Increases
M	Moves
P	Produces
S	Changes State

+	Simulates
=	Regulates
C	Consumes
D	Decreases
F	Flows
I	Increases
M	Moves
P	Produces
S	Changes State






FIG. 5C




FIG. 6A

+	Simulates
=	Regulates
C	Consumes
D	Decreases
F	Flows
I	Increases
M	Moves
P	Produces
S	Changes State




FIG. 6B






FIG. 7




FIG. 8A




FIG. 8B




FIG. 8C




FIG. 9A

+ Stimulates
 = Regulates
 C Consumes
 D Decreases
 F Flows
 I Increases
 M Moves
 P Produces
 S Changes State




FIG. 9B




FIG. 9C




FIG. 9D





FIG. 10A




FIG. 10B




FIG. 10C




FIG. 10D




FIG. 11A




FIG. 11B




FIG. 12




FIG. 13







FIG. 14




vector sum index 0
FIG. 15A




vector sum index 1
FIG. 15B




vector sum index 2
FIG. 15C




vector sum index 3
FIG. 15D




vector sum index 4
FIG. 15E



vector sum index 5
FIG. 15F



vector sum index 6
FIG. 15G



vector sum index 7
FIG. 15H

ApoB-100 Particle Composition

Reference Virtual Patient
Simulated HMG CoA-Reductase Inhibition
(80 mg atorvastatin/day)




Figure 16A




Figure 16B

ApoB-100 Particle Composition

Type IIb Dyslipidemic Virtual Patient
Simulated HMG CoA-Reductase Inhibition
(40 mg atorvastatin/day)




Figure 16C




Figure 16D

HDL Particle Composition

Reference Virtual Patient
 Simulated HMG CoA-Reductase Inhibition
 (80 mg atorvastatin/day)




Figure 17A




Figure 17B

HDL Particle Composition

Type IIb Dyslipidemic Virtual Patient
Simulated HMG CoA-Reductase Therapy
(40 mg atorvastatin/day)




Figure 17D

Type IIb Dyslipidemic Virtual Patient




Figure 17C

Treatment Effects on Plasma Lipids Reference Virtual Patient





Figure 18A



Therapy: Simulated HMG-CoA Reductase Inhibition
(80 mg atorvastatin/day)

Figure 18B

**Treatment Effects on Plasma Lipids
Type IIb Dyslipidemic Virtual Patient**





Figure 18C



*Therapy: Simulated HMG CoA-Reductase Inhibition
(40 mg atorvastatin/day)*

Figure 18D